• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本先天性糖基化障碍患者的临床和分子特征

Clinical and Molecular Features of Patients With Congenital Disorders of Glycosylation in Japan.

作者信息

Okamoto Nobuhiko, Kadoya Machiko, Wada Yoshinao

机构信息

Department of Medical Genetics Osaka Women's and Children's Hospital Izumi Japan.

Department of Molecular Medicine Research Institute, Osaka Women's and Children's Hospital Izumi Japan.

出版信息

JIMD Rep. 2025 Apr 4;66(3):e70011. doi: 10.1002/jmd2.70011. eCollection 2025 May.

DOI:10.1002/jmd2.70011
PMID:40191061
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11969085/
Abstract

Congenital disorders of glycosylation (CDG) are a heterogeneous group of diseases caused by defects in various steps of the glycosylation pathway. There are over 200 known human glycosylation-related disorders. Many of these defects lead to multisystemic manifestations, commonly involving the central nervous system, with symptoms ranging from mild to severe. The phenotypic presentation of CDG can vary significantly. Identifying altered protein glycosylation is crucial for accurate diagnosis. Our research institute has contributed to the CDG diagnostic support center in Japan, developing new analytical techniques utilizing mass spectrometry. These techniques allow for the identification of defects in -glycosylation, -glycosylation, and combined glycosylation pathways. Advances in genetic analysis, including whole exome sequencing, have revealed that certain types of CDG are more prevalent than previously recognized. We have contributed to the molecular diagnosis of 66 CDG patients in Japan. Although PMM2-CDG is the most common form of CDG, it was only detected in 17% of the patients in the present study, suggesting that its incidence is much lower in Japan compared to European countries. We also conducted a comprehensive review of case reports of CDG in Japan, further describing the clinical and molecular spectrum of the disease in this population.

摘要

先天性糖基化障碍(CDG)是一组由糖基化途径不同步骤缺陷引起的异质性疾病。已知有200多种人类糖基化相关疾病。其中许多缺陷会导致多系统表现,通常累及中枢神经系统,症状从轻到重不等。CDG的表型表现差异很大。识别蛋白质糖基化改变对于准确诊断至关重要。我们的研究所为日本的CDG诊断支持中心做出了贡献,开发了利用质谱的新分析技术。这些技术能够识别N-糖基化、O-糖基化和联合糖基化途径中的缺陷。包括全外显子测序在内的基因分析进展表明,某些类型的CDG比以前认识到的更为普遍。我们为日本66例CDG患者的分子诊断做出了贡献。尽管PMM2-CDG是最常见的CDG形式,但在本研究中仅在17%的患者中检测到,这表明其在日本的发病率与欧洲国家相比要低得多。我们还对日本CDG病例报告进行了全面综述,进一步描述了该人群中该疾病的临床和分子谱。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffc4/11969085/415077a0381a/JMD2-66-e70011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffc4/11969085/5eb8d3714f0a/JMD2-66-e70011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffc4/11969085/5d26a3d36dda/JMD2-66-e70011-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffc4/11969085/415077a0381a/JMD2-66-e70011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffc4/11969085/5eb8d3714f0a/JMD2-66-e70011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffc4/11969085/5d26a3d36dda/JMD2-66-e70011-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffc4/11969085/415077a0381a/JMD2-66-e70011-g002.jpg

相似文献

1
Clinical and Molecular Features of Patients With Congenital Disorders of Glycosylation in Japan.日本先天性糖基化障碍患者的临床和分子特征
JIMD Rep. 2025 Apr 4;66(3):e70011. doi: 10.1002/jmd2.70011. eCollection 2025 May.
2
Phenotypic and genotypic spectrum of congenital disorders of glycosylation type I and type II.I型和II型糖基化先天性疾病的表型和基因型谱。
Mol Genet Metab. 2017 Mar;120(3):235-242. doi: 10.1016/j.ymgme.2016.12.014. Epub 2017 Jan 3.
3
Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain.西班牙非磷酸甘露糖变位酶 2 N-连接性先天性糖基化障碍的临床和分子诊断。
Clin Genet. 2019 May;95(5):615-626. doi: 10.1111/cge.13508. Epub 2019 Apr 3.
4
A Population-Based Study on Congenital Disorders of Protein N- and Combined with O-Glycosylation Experience in Clinical and Genetic Diagnosis.一项基于人群的蛋白质N-糖基化先天性疾病及合并O-糖基化疾病的临床与基因诊断经验研究
J Pediatr. 2017 Apr;183:170-177.e1. doi: 10.1016/j.jpeds.2016.12.060. Epub 2017 Jan 27.
5
Cardiomyopathy, an uncommon phenotype of congenital disorders of glycosylation: Recommendations for baseline screening and follow-up evaluation.心肌病,一种罕见的糖基化先天性疾病表型:基线筛查和随访评估建议。
Mol Genet Metab. 2024 Aug;142(4):108513. doi: 10.1016/j.ymgme.2024.108513. Epub 2024 Jun 13.
6
Clinical and whole-exome sequencing findings in two siblings from Hani ethnic minority with congenital glycosylation disorders.两例哈尼族先天性糖基化障碍患者的临床和全外显子组测序结果
BMC Med Genet. 2019 Nov 14;20(1):181. doi: 10.1186/s12881-019-0902-z.
7
Congenital disorders of glycosylation with emphasis on cerebellar involvement.以小脑受累为重点的先天性糖基化障碍
Semin Neurol. 2014 Jul;34(3):357-66. doi: 10.1055/s-0034-1387197. Epub 2014 Sep 5.
8
Clinical, biochemical and molecular phenotype of congenital disorders of glycosylation: long-term follow-up.先天性糖基化障碍的临床、生化和分子表型:长期随访。
Orphanet J Rare Dis. 2021 Jan 6;16(1):17. doi: 10.1186/s13023-020-01657-5.
9
Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals.磷酸甘露糖变位酶 2 先天性糖基化障碍(PMM2-CDG)患者报告结局:倾听患者和医疗保健专业人员的心声。
Orphanet J Rare Dis. 2022 Oct 29;17(1):398. doi: 10.1186/s13023-022-02551-y.
10
Primary ovarian insufficiency in a female with phosphomannomutase-2 gene (PMM2) mutations for congenital disorder of glycosylation.先天性糖基化障碍伴磷酸甘露糖变位酶 2 基因(PMM2)突变导致的女性原发性卵巢功能不全。
Endocr J. 2021 May 28;68(5):605-611. doi: 10.1507/endocrj.EJ20-0706. Epub 2021 Mar 11.

引用本文的文献

1
Approaches to diagnostic screening for congenital disorders of glycosylation and its prevalence in Japan.先天性糖基化障碍的诊断筛查方法及其在日本的患病率
J Hum Genet. 2025 Jul 2. doi: 10.1038/s10038-025-01362-w.

本文引用的文献

1
Mass Spectrometry as a First-Line Diagnostic Aid for Congenital Disorders of Glycosylation.质谱分析法作为糖基化先天性疾病的一线诊断辅助手段
Mass Spectrom (Tokyo). 2025;14(1):A0169. doi: 10.5702/massspectrometry.A0169. Epub 2025 Feb 8.
2
Clinical severity and cardiac phenotype in phosphomannomutase 2-congenital disorders of glycosylation : Insights into genetics and management recommendations.磷酸甘露糖变位酶2-先天性糖基化障碍的临床严重程度和心脏表型:遗传学见解与管理建议
J Inherit Metab Dis. 2025 Jan;48(1):e12826. doi: 10.1002/jimd.12826. Epub 2024 Dec 5.
3
Treatment of congenital disorders of glycosylation: An overview.
先天性糖基化障碍的治疗:概述。
Mol Genet Metab. 2024 Sep-Oct;143(1-2):108567. doi: 10.1016/j.ymgme.2024.108567. Epub 2024 Aug 18.
4
In vitro treatment with liposome-encapsulated Mannose-1-phosphate restores N-glycosylation in PMM2-CDG patient-derived fibroblasts.脂质体包裹的甘露糖-1-磷酸体外处理可恢复 PMM2-CDG 患者来源成纤维细胞中的 N-糖基化。
Mol Genet Metab. 2024 Sep-Oct;143(1-2):108531. doi: 10.1016/j.ymgme.2024.108531. Epub 2024 Jul 1.
5
Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort.糖基化先天性疾病前沿研究联盟,一项针对自然病史队列中280名个体的第5年横断面研究报告。
Mol Genet Metab. 2024 Aug;142(4):108509. doi: 10.1016/j.ymgme.2024.108509. Epub 2024 Jun 6.
6
Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.脂质体包裹的甘露糖-1-磷酸疗法可改善不同先天性糖基化障碍中的整体N-糖基化。
Mol Genet Metab. 2024 Jun;142(2):108487. doi: 10.1016/j.ymgme.2024.108487. Epub 2024 May 7.
7
Clinical and biochemical footprints of congenital disorders of glycosylation: Proposed nosology.先天性糖基化障碍的临床和生化特征:拟议的分类学。
Mol Genet Metab. 2024 May;142(1):108476. doi: 10.1016/j.ymgme.2024.108476. Epub 2024 Apr 10.
8
Progressive myoclonic epilepsy as an expanding phenotype of NGLY1-associated congenital deglycosylation disorder: A case report and review of the literature.进展性肌阵挛癫痫作为 NGLY1 相关先天性去糖基化障碍的扩展表型:病例报告及文献复习。
Eur J Med Genet. 2024 Feb;67:104895. doi: 10.1016/j.ejmg.2023.104895. Epub 2023 Dec 7.
9
Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.神经表现 PMM2-先天性糖基化障碍 (PMM2-CDG):临床放射学特征的见解、随访建议和未来方向。
Genet Med. 2024 Feb;26(2):101027. doi: 10.1016/j.gim.2023.101027. Epub 2023 Nov 10.
10
Association between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management.PMM2-CDG患者急性并发症与止血异常之间的关联:一项多中心研究的数据及急性处理建议
Mol Genet Metab. 2023 Nov;140(3):107674. doi: 10.1016/j.ymgme.2023.107674. Epub 2023 Jul 31.